패혈증 진단 시장 : 규모, 점유율, 성장, 산업 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of sepsis diagnostics Market

The global sepsis diagnostics market size was valued at USD 1,003.95 million in 2025 and is projected to grow from USD 1,099.22 million in 2026 to USD 2,399.34 million by 2034, exhibiting a CAGR of 10.20% during the forecast period (2026-2034). North America dominated the market in 2025, accounting for a 51.50% share, driven by high disease incidence, favorable reimbursement policies, and rapid adoption of advanced diagnostic technologies.

Sepsis is a life-threatening condition caused by the body's extreme response to infection, leading to tissue damage, organ failure, and potentially death. Bacterial infections are the most common cause, though viral and fungal infections can also trigger the condition. The three stages include sepsis, severe sepsis, and septic shock. According to the World Health Organization (WHO), approximately 49 million people were affected globally in 2017, resulting in 11 million deaths, highlighting the urgent need for early and accurate diagnostics.

Market Dynamics

The rising global incidence of sepsis is a major factor driving market growth. In the U.S. alone, around 1.7 million adults develop sepsis annually, with nearly 350,000 deaths occurring during hospitalization or hospice care. Increased hospitalization rates and healthcare-associated infections (HAIs) further elevate demand for reliable diagnostic solutions.

Favorable reimbursement policies, especially in developed countries, support hospital admissions and diagnostic procedures. Additionally, growing awareness initiatives by global organizations such as the Global Sepsis Alliance and WHO are promoting early detection and standardized treatment protocols.

The COVID-19 pandemic had a slightly positive impact on the market in 2020 due to increased sepsis incidence among infected patients. By 2021, patient visits and company revenues returned to pre-pandemic levels, supporting stable growth through the forecast period.

Key Market Trends

A prominent trend in the sepsis diagnostics market is the increasing adoption of rapid diagnostic and point-of-care (POC) technologies. These solutions provide faster and more accurate results compared to conventional methods, enabling timely clinical intervention. Rapid tests reduce dependency on extensive laboratory infrastructure and skilled personnel, addressing workforce shortages in many healthcare systems.

In November 2023, Inflammatix completed technical development of its TriVerity Acute Infection and Sepsis Test System and received U.S. FDA Breakthrough Device Designation, accelerating commercialization efforts. Such technological advancements are significantly enhancing diagnostic speed and efficiency.

Growth Drivers

The exponential rise in global sepsis cases continues to fuel demand for effective diagnostic solutions. Hospitalized patients are particularly vulnerable, with studies indicating that nearly one in three hospital deaths involves sepsis. The increasing burden on healthcare systems strengthens the need for early detection technologies.

Growing awareness in emerging markets further contributes to market expansion. Government and non-government initiatives are promoting screening programs, education, and implementation of sepsis bundles to reduce mortality. Campaigns such as the Global Maternal Sepsis Study and Campaign (GLOSS) are improving awareness and encouraging diagnostic adoption globally.

Restraining Factors

Despite strong growth prospects, high diagnostic costs limit broader adoption. Sepsis diagnosis typically requires multiple tests, increasing overall expenses. For example, annual direct and indirect costs related to sepsis in the U.K. are estimated at USD 9.24 billion. In emerging countries, individual test costs can create financial burdens for patients, restricting access to timely diagnosis.

Additionally, the absence of a single definitive diagnostic test and reliance on combined clinical assessments pose operational challenges.

Market Segmentation Analysis

By Product Type

The reagents & consumables segment dominated with a 77.22% market share in 2026, driven by recurring demand across hospitals and laboratories. The instruments segment is projected to grow steadily due to technological advancements and new product launches.

By Technology

The microbiology segment accounted for 58.85% of the market share in 2026, owing to widespread use of blood cultures and cost-effectiveness. Immunoassays represent the second-largest segment, while molecular diagnostics are gaining traction due to higher sensitivity and faster results.

By Method

The automated segment held a dominant 93.26% share in 2026, attributed to high specificity and rapid pathogen detection capabilities. Conventional methods maintain relevance in low-income settings due to affordability.

By Test Type

Laboratory tests dominate due to high hospitalization rates and ICU admissions. However, point-of-care tests are expected to witness the highest growth rate due to their cost-effectiveness and rapid results.

By Pathogen

The bacterial segment holds the largest share, as bacterial infections remain the leading cause of sepsis. Fungal diagnostics represent the second-largest segment.

By End User

Hospitals & clinics dominate the market, given the high volume of ICU admissions and in-hospital diagnostics.

Regional Insights

In 2025, North America generated USD 517.1 million, maintaining market leadership. Strong healthcare infrastructure, technological innovation, and government support drive regional growth.

Europe ranks as the second-largest market, supported by regulatory approvals and skilled professionals. Asia Pacific is projected to experience significant growth due to rising awareness, updated clinical guidelines (such as Japan's J-SSCG 2021), and expanding healthcare infrastructure.

Key Industry Players

Leading companies include bioMerieux SA, Danaher, Thermo Fisher Scientific Inc., BD, Abbott, Siemens Healthcare GmbH, T2 Biosystems, Luminex Corporation (DiaSorin S.p.A.), and Bruker. Strategic partnerships, regulatory approvals, and product launches are strengthening competitive positioning.

Conclusion

The global sepsis diagnostics market is poised for strong expansion, growing from USD 1,003.95 million in 2025 to USD 2,399.34 million by 2034, at a CAGR of 10.20%. Increasing disease prevalence, rapid adoption of automated and point-of-care diagnostics, and strong awareness initiatives are driving growth. Although high diagnostic costs pose challenges, technological advancements and global healthcare improvements are expected to sustain long-term market expansion across key regions.

Segmentation By Product Type

• Instruments
• Reagents & Consumables

By Technology

• Microbiology
• Molecular Diagnostics
• Immunoassays
• Others

By Method

• Conventional
• Automated

By Test Type

• Laboratory Tests
• Point-of-Care Tests

By Pathogen

• Bacterial
• Fungal
• Others

By End User

• Hospitals & Clinics
• Diagnostic Centers
• Others

By Region

• North America (By Product Type, Technology, Method, Test Type, Pathogen, End User, and Country)
  • U.S. (By Product Type)
  • Canada (By Product Type)
• Europe (By Product Type, Technology, Method, Test Type, Pathogen, End User, and Country/Sub-Region)
  • Germany (By Product Type)
  • U.K. (By Product Type)
  • France (By Product Type)
  • Italy (By Product Type)
  • Spain (By Product Type)
  • Rest of Europe (By Product Type)
• Asia Pacific (By Product Type, Technology, Method, Test Type, Pathogen, End User, and Country/Sub-Region)
  • China (By Product Type)
  • India (By Product Type)
  • Japan (By Product Type)
  • Australia (By Product Type)
  • Rest of Asia Pacific (By Product Type)
• Rest of the World (By Product Type, Technology, Method, Test Type, Pathogen, and End User)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Sepsis Incidence, By Key Regions, 2025
• 4.2. New Product Launches
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.4. Technological Advancements in Sepsis Diagnostics
• 4.5. Regulatory & Reimbursement Scenario, Key Regions
• 4.6. Impact of COVID-19 Pandemic on Sepsis Diagnostics Market

5. Global Sepsis Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Instruments
  • 5.1.2. Reagents & Consumables
• 5.2. Market Analysis, Insights and Forecast - By Technology
  • 5.2.1. Microbiology
  • 5.2.2. Molecular Diagnostics
  • 5.2.3. Immunoassays
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Method
  • 5.3.1. Conventional
  • 5.3.2. Automated
• 5.4. Market Analysis, Insights and Forecast - By Test Type
  • 5.4.1. Laboratory Tests
  • 5.4.2. Point-of-Care Tests
• 5.5. Market Analysis, Insights and Forecast - By Pathogen
  • 5.5.1. Bacterial
  • 5.5.2. Fungal
  • 5.5.3. Other Pathogens
• 5.6. Market Analysis, Insights and Forecast - By End User
  • 5.6.1. Hospitals & Clinics
  • 5.6.2. Diagnostic Centres
  • 5.6.3. Others
• 5.7. Market Analysis, Insights and Forecast - By Region
  • 5.7.1. North America
  • 5.7.2. Europe
  • 5.7.3. Asia Pacific
  • 5.7.4. Rest of the World

6. North America Sepsis Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Instruments
  • 6.1.2. Reagents & Consumables
• 6.2. Market Analysis, Insights and Forecast - By Technology
  • 6.2.1. Microbiology
  • 6.2.2. Molecular Diagnostics
  • 6.2.3. Immunoassays
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Method
  • 6.3.1. Conventional
  • 6.3.2. Automated
• 6.4. Market Analysis, Insights and Forecast - By Test Type
  • 6.4.1. Laboratory Tests
  • 6.4.2. Point-of-Care Tests
• 6.5. Market Analysis, Insights and Forecast - By Pathogen
  • 6.5.1. Bacterial
  • 6.5.2. Fungal
  • 6.5.3. Other Pathogens
• 6.6. Market Analysis, Insights and Forecast - By End User
  • 6.6.1. Hospitals & Clinics
  • 6.6.2. Diagnostic Centres
  • 6.6.3. Others
• 6.7. Market Analysis, Insights and Forecast - By Country
  • 6.7.1. U.S.
    • 6.7.1.1. By Product Type
  • 6.7.2. Canada
    • 6.7.2.1. By Product Type

7. Europe Sepsis Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Instruments
  • 7.1.2. Reagents & Consumables
• 7.2. Market Analysis, Insights and Forecast - By Technology
  • 7.2.1. Microbiology
  • 7.2.2. Molecular Diagnostics
  • 7.2.3. Immunoassays
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Method
  • 7.3.1. Conventional
  • 7.3.2. Automated
• 7.4. Market Analysis, Insights and Forecast - By Test Type
  • 7.4.1. Laboratory Tests
  • 7.4.2. Point-of-Care Tests
• 7.5. Market Analysis, Insights and Forecast - By Pathogen
  • 7.5.1. Bacterial
  • 7.5.2. Fungal
  • 7.5.3. Other Pathogens
• 7.6. Market Analysis, Insights and Forecast - By End User
  • 7.6.1. Hospitals & Clinics
  • 7.6.2. Diagnostic Centres
  • 7.6.3. Others
• 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.7.1. Germany
    • 7.7.1.1. By Product Type
  • 7.7.2. U.K.
    • 7.7.2.1. By Product Type
  • 7.7.3. France
    • 7.7.3.1. By Product Type
  • 7.7.4. Spain
    • 7.7.4.1. By Product Type
  • 7.7.5. Italy
    • 7.7.5.1. By Product Type
  • 7.7.6. Rest of Europe
    • 7.7.6.1. By Product Type

8. Asia Pacific Sepsis Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Instruments
  • 8.1.2. Reagents & Consumables
• 8.2. Market Analysis, Insights and Forecast - By Technology
  • 8.2.1. Microbiology
  • 8.2.2. Molecular Diagnostics
  • 8.2.3. Immunoassays
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Method
  • 8.3.1. Conventional
  • 8.3.2. Automated
• 8.4. Market Analysis, Insights and Forecast - By Test Type
  • 8.4.1. Laboratory Tests
  • 8.4.2. Point-of-Care Tests
• 8.5. Market Analysis, Insights and Forecast - By Pathogen
  • 8.5.1. Bacterial
  • 8.5.2. Fungal
  • 8.5.3. Other Pathogens
• 8.6. Market Analysis, Insights and Forecast - By End User
  • 8.6.1. Hospitals & Clinics
  • 8.6.2. Diagnostic Centres
  • 8.6.3. Others
• 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.7.1. China
    • 8.7.1.1. By Product Type
  • 8.7.2. India
    • 8.7.2.1. By Product Type
  • 8.7.3. Japan
    • 8.7.3.1. By Product Type
  • 8.7.4. Australia
    • 8.7.4.1. By Product Type
  • 8.7.5. Rest of Asia Pacific
    • 8.7.5.1. By Product Type

9. Rest of the World Sepsis Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Instruments
  • 9.1.2. Reagents & Consumables
• 9.2. Market Analysis, Insights and Forecast - By Technology
  • 9.2.1. Microbiology
  • 9.2.2. Molecular Diagnostics
  • 9.2.3. Immunoassays
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Method
  • 9.3.1. Conventional
  • 9.3.2. Automated
• 9.4. Market Analysis, Insights and Forecast - By Test Type
  • 9.4.1. Laboratory Tests
  • 9.4.2. Point-of-Care Tests
• 9.5. Market Analysis, Insights and Forecast - By Pathogen
  • 9.5.1. Bacterial
  • 9.5.2. Fungal
  • 9.5.3. Other Pathogens
• 9.6. Market Analysis, Insights and Forecast - By End User
  • 9.6.1. Hospitals & Clinics
  • 9.6.2. Diagnostic Centres
  • 9.6.3. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. T2 Biosystems, Inc.
    • 10.2.1.1. Overview
    • 10.2.1.2. Product
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. financials (Based on Availability)
  • 10.2.2. Danaher
    • 10.2.2.1. Overview
    • 10.2.2.2. Product
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. financials (Based on Availability)
  • 10.2.3. Abbott
    • 10.2.3.1. Overview
    • 10.2.3.2. Product
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. financials (Based on Availability)
  • 10.2.4. bioMerieux SA
    • 10.2.4.1. Overview
    • 10.2.4.2. Product
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. financials (Based on Availability)
  • 10.2.5. Thermo Fisher Scientific Inc.
    • 10.2.5.1. Overview
    • 10.2.5.2. Product
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. financials (Based on Availability)
  • 10.2.6. Luminex Corporation (DiaSorin S.p.A.)
    • 10.2.6.1. Overview
    • 10.2.6.2. Product
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. financials (Based on Availability)
  • 10.2.7. BD (Becton, Dickinson, and Company)
    • 10.2.7.1. Overview
    • 10.2.7.2. Product
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. financials (Based on Availability)
  • 10.2.8. Bruker
    • 10.2.8.1. Overview
    • 10.2.8.2. Product
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. financials (Based on Availability)
  • 10.2.9. Siemens Healthcare GmbH
    • 10.2.9.1. Overview
    • 10.2.9.2. Product
    • 10.2.9.3. SWOT Analysis
    • 10.2.9.4. Recent Developments
    • 10.2.9.5. Strategies
    • 10.2.9.6. financials (Based on Availability)